Are Savings from Secondary Prevention (Such as Antihypertensive Therapy after Stroke or after Carotid Endarterectomy) Quantifiable?
With recent debates on potential cost savings in health care, cost considerations implied by stroke prevention and treatment strategies should not be left unattended. It is estimated that by primary prevention, through antihypertensive therapy as example a main saving on stroke mortality results. For the US, aggressive identification and management of hypertension has declined the incidence of intracerebral hemorrhage. Calculated on the basis of 500,000 new strokes/year in the US, it is estimated to prevent 246,000, respectively 49.3% of strokes alone by treatment of hypertension [Alexandrov et al., 1997]. For secondary prevention the data are not that clear, so that no statement in respect to cost analysis can be given. Savings could be calculated from the reduction of stroke occurrence known from controlled randomized trials. After carotid endarterectomy in severe symptomatic stenosis (> 70%) every sixth stroke due to this condition can be avoided. The overall costs for carotid endar
Related Questions
- Are Savings from Secondary Prevention (Such as Antihypertensive Therapy after Stroke or after Carotid Endarterectomy) Quantifiable?
- Should people with asymptomatic carotid artery stenosis undergo endarterectomy for primary stroke prevention?
- WHAT IS THE OPTIMAL WARFARIN DOSE FOR SECONDARY PREVENTION OF STROKE?
